In a randomized, double-blind clinical trial, adjuvant atorvastatin improved symptoms of depression and blood lipid values in patients suffering from severe major depressive disorder

Journal of Psychiatric Research

Volumn 58, Issue , 2014, Pages 109-114

  Haghighi, Mohammad ^a   Khodakarami, Saeed ^a   Jahangard, Leila ^a   Ahmadpanah, Mohammad ^a   Bajoghli, Hafez ^b,c   Holsboer Trachsler, Edith ^d   Brand, Serge ^d,e  

^a HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MAHIDOL UNIVERSITY   (Thailand)

^d UNIVERSITY OF BASEL   (Switzerland)

^e UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Atorvastatin; Blood lipid values; Major depressive disorder; Randomized double blind clinical trial

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; CHOLESTEROL; CITALOPRAM; CREATINE KINASE; HIGH DENSITY LIPOPROTEIN; LACTATE DEHYDROGENASE; LIPID; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; PYRROLE DERIVATIVE;

ADD ON THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HAMILTON SCALE; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONOTHERAPY; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; ADULT; ANALYSIS OF VARIANCE; BLOOD; CHI SQUARE DISTRIBUTION; DEPRESSIVE DISORDER, MAJOR; FOLLOW UP; PSYCHOLOGICAL RATING SCALE; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANALYSIS OF VARIANCE; ANTICHOLESTEREMIC AGENTS; CHI-SQUARE DISTRIBUTION; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HUMANS; LIPIDS; MALE; PSYCHIATRIC STATUS RATING SCALES; PYRROLES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84912575754     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2014.07.018     Document Type: Article

References (36)

1. American Psychiatric Association Diagnostic and statistical manual of mental disorders 2013, American Psychiatric Publishing, Arlington, VA. 5th ed.
2. Andrade C. Selective serotonin reuptake inhibitor drug interactions in patients receiving statins. JClin Psychiatry 2014, 75. e95-9.
3. Bauer M., Pfennig A., Severus E., Whybrow P.C., Angst J., Möller H.J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry 2013, 14:334-385. World Federation of Societies of Biological Psychiatry, Task Force on Unipolar Depressive DisordersTask Force on Unipolar Depressive Disorders.
4. Brunoni A.R., Baeken C., Machado-Vieira R., Gattaz W.F., Vanderhasselt M.A. BDNF blood levels after electroconvulsive therapy in patients with mood disorders: a systematic review and meta-analysis. World J Biol Psychiatry 2014, 15:411-418.
5. Cassano P., Fava M. Depression and public health - an overview. JPsychosom Res 2002, 53:849-857.
6. Castrén E. Is mood chemistry?. Nat Rev Neurosci 2005, 6:241-246.
7. Cooney G.M., Dwan K., Greig C.A., Lawlor D.A., Rimer J., Waugh F.R., et al. Exercise for depression. Cochrane Database Syst Rev 2013, 9:CD004366.
8. Drug Bank, Update Date 2011-11-09. http://www.drugbank.ca/drugs/DB00857S.
9. Feng L., Tan C.H., Merchant R.A., Ng T.P. Association between depressive symptoms and use of HMG-CoA reductase inhibitors (statins), corticosteroids and histamine H(2) receptor antagonists in community-dwelling older persons: cross-sectional analysis of a population-based cohort. Drugs Aging 2008, 25:795-805.
10. Ghanizadeh A., Hedayati A. Augmentation of fluoxetine with lovastatin for treating major depressive disorder, a randomized double-blind placebo placeboled-clinical trial. Depress Anxiety 2013, 30:1084-1088.
11. Grawe K. Neuropsychotherapie [Neuropsychotherapy] 2004, Hogrefe, Göttingen.
12. Haghighi M., Salehi I., Erfani P., Jahangard L., Bajoghli H., Holsboer-Trachsler E., et al. Additional ECT increases BDNF-levels in patients suffering from major depressive disorders compared to patients treated with citalopram only. JPsychiatr Res 2013, 47:908-915.
13. Hair J.F., Black W.C., Babin B.J., Anderson R.E. Multivariate data analysis 2009, Prentice Hall, Upper Saddle River NJ. 7th ed.
14. Hamilton M. Arating scale for depression. JNeurol Neurosurg Psychiatry 1960, 23:56-62.
15. Hashimoto K. Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev 2009, 65:105-123.
16. Hasler G. Pathophysiology of depression: do we have any solid evidence of interest to clinicians?. World Psychiatry 2010, 9:155-161.
17. Irwin S.A., Iglewicz A. Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care. JPalliat Med 2010, 13:903-908.
18. Josefsson T., Lindwall M., Archer T. Physical exercise atorvastatin in depressive disorders: meta-analysis and systematic review. Scand J Med Sci Sports 2014, 24:259-272.
19. Kanfer F.H., Reinecker H., Schmelzer D. Selbstmanagement-Therapie: Ein Lehrbuch für die klinische Praxis 2012, Springer, Berlin, New York. 5th ed.
20. Kellner C.H., Greenberg R.M., Murrough J.W., Bryson E.O., Briggs M.C., Pasculli R.M. ECT in treatment-resistant depression. Am J Psychiatry 2012, 169:1238-1244.
21. Lopresti A.L., Maker G.L., Hood S.D., Drummond P.D. Areview of peripheral biomarkers in major depression: the potential of inflammatory and oxidative stress biomarkers. Prog Neuropsychopharmacol Biol Psychiatry 2014, 48:102-111.
22. Ludka F.K., Zomkowski A.D., Cunha M.P., Dal-Cim T., Zeni A.L., Rodrigues A.L., et al. Acute atorvastatin treatment exerts antidepressant-like effect in mice via the L-arginine-nitric oxide-cyclic guanosine monophosphate pathway and increases BDNF levels. Eur Neuropsychopharmacol 2013, 23:400-412.
23. Mandas A., Congiu M.G., Abete C., Dessi S., Manconi P.E., Musio M., et al. Cognitive decline and depressive symptoms in late-life are associated with statin use: evidence from a population-based study of Sardinian old people living in their own home. Neurol Res 2014, 36:247-254.
24. Mikoteit T., Beck J., Eckert A., Hemmeter U., Brand S., Bischof R., et al. High baseline BDNF serum levels and early psychopathological improvement are predictive of treatment outcome in major depression. Psychopharmacol (Berl) 2014, 231:2955-2965.
25. Mota-Pereira J., Silverio J., Carvalho S., Ribeiro J.C., Fonte D., Ramos J. Moderate exercise improves depression parameters in treatment-resistant patients with major depressive disorder. JPsychiatr Res 2011, 45:1005-1011.
26. Murray C.J.L., Lopez A.D. Global mortality, disability, and the contribution of risk factors: global burden of disease study. Lancet 1997, 349:1436-1442.
27. O'Neil A., Sanna L., Redlich C., Sanderson K., Jacka F., Williams L.J., et al. The impact of statins on psychological wellbeing: a systematic review and meta-analysis. BMC Med 2012, 10:154.
28. Otte C., Zhao S., Whooley M.A. Statin use and risk of depression in patients with coronary heart disease: longitudinal data from the heart and soul Study. JClin Psychiatry 2012, 73:610-615.
29. Parsaik A.K., Singh B., Hassan Murad M., Singh K., Mascarenhas S.S., Williams M.D., et al. Statins use and risk of depression: a systematic review and meta-analysis. JAffect Disord 2014, 160:62-67.
30. Reichenpfader U., Gartlehner G., Morgan L.C., Greenblatt A., Nussbaumer B., Hansen R.A., et al. Sexual dysfunction associated with second-generation antidepressants in patients with major depressive disorder: results from a systematic review with network meta-analysis. Drug Saf 2014, 37:19-31.
31. Salehi I., Hosseini S.M., Haghighi M., Jahangard L., Bajoghli H., Gerber M., et al. Electroconvulsive therapy and aerobic exercise training increased BDNF and ameliorated depressive symptoms in patients suffering from treatment-resistant major depressive disorder. JPsych Res 2014, 57:117-124.
32. Stafford L., Berk M. The use of statins after a cardiac atorvastatin is associated with reduced risk of subsequent depression: proof of concept for the inflammatory and oxidative hypotheses of depression?. JClin Psychiatry 2011, 72:1229-1235.
33. Tuccori M., Montagnani S., Mantarro S., Capogrosso-Sansone A., Ruggiero E., Saporiti A., et al. Neuropsychiatric adverse events associated with statins: epidemiology, pathophysiology, prevention and management. CNS Drugs 2014, 28:249-272.
34. Wolkowitz O.M., Wolf J., Shelly W., Rosser R., Burke H.M., Lerner G.K., et al. Serum BDNF levels before treatment predict SSRI response in depression. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:1623-1630.
35. Yang C.C., Jick S.S., Jick H. Lipid-lowering drugs and the risk of depression and suicidal behavior. Arch Intern Med 2003, 163:1926-1932.
36. Young-Xu Y., Chan K.A., Liao J.K., Ravid S., Blatt C.M. Long-term statin use and psychological well-being. JAm Coll Cardiol 2003, 42:690-697.